Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator Applications and currently in Phase II for Meningioma. According to GlobalData, Phase II drugs for Meningioma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lutetium Lu 177 dotatate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lutetium Lu 177 dotatate overview
Lutetium Lu-177 dotatate or Lutetium (177Lu) oxodotreotide (Lutathera) is a radiolabelled peptide, acts as an antitumor agent.It is formulated as injectable solution for intravenous route of administration. Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
Lutathera is under development for the treatment of metastatic breast carcinoma, , relapsed or refractory small-cell lung cancer, medullary thyroid cancer, parathyroid carcinoma, pituitary carcinoma, progressive meningioma, refractory or relapsed high-risk neuroblastoma, gastroenteropancreatic neuroendocrine tumors, pheochromocytoma, paraganglioma and metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) including inoperable progressive midgut carcinoid, pheochromocytoma, paraganglioma, glioblastoma, recurrent glioblastoma and metastatic prostate cancer with neuroendocrine differentiation. It is administered through intra-arterial hepatic (IAH) injection.
Advanced Accelerator Applications overview
Advanced Accelerator Applications (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. It is also involved in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). It’s key brand portfolio comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, Lysakare, Dopaview, Padoview and Lumark. AAA is headquartered in Rueil-Malmaison Cedex, Ile-de-France, France.
For a complete picture of Lutetium Lu 177 dotatate’s drug-specific PTSR and LoA scores, buy the report here.